Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.60
AVEO's Cash to Debt is ranked lower than
66% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. AVEO: 3.60 )
Ranked among companies with meaningful Cash to Debt only.
AVEO' s Cash to Debt Range Over the Past 10 Years
Min: 1.54  Med: 4.10 Max: 9.15
Current: 3.6
1.54
9.15
Equity to Asset 0.43
AVEO's Equity to Asset is ranked lower than
77% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AVEO: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
AVEO' s Equity to Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.43 Max: 0.76
Current: 0.43
-3.21
0.76
F-Score: 3
Z-Score: -15.44
M-Score: -1.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -65.33
AVEO's Operating margin (%) is ranked higher than
50% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. AVEO: -65.33 )
Ranked among companies with meaningful Operating margin (%) only.
AVEO' s Operating margin (%) Range Over the Past 10 Years
Min: -8035.89  Med: -198.82 Max: 20.59
Current: -65.33
-8035.89
20.59
Net-margin (%) -78.87
AVEO's Net-margin (%) is ranked lower than
52% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. AVEO: -78.87 )
Ranked among companies with meaningful Net-margin (%) only.
AVEO' s Net-margin (%) Range Over the Past 10 Years
Min: -8277.57  Med: -212.81 Max: 18.59
Current: -78.87
-8277.57
18.59
ROE (%) -85.70
AVEO's ROE (%) is ranked lower than
78% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. AVEO: -85.70 )
Ranked among companies with meaningful ROE (%) only.
AVEO' s ROE (%) Range Over the Past 10 Years
Min: -116.49  Med: -79.30 Max: 20.76
Current: -85.7
-116.49
20.76
ROA (%) -31.40
AVEO's ROA (%) is ranked lower than
55% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. AVEO: -31.40 )
Ranked among companies with meaningful ROA (%) only.
AVEO' s ROA (%) Range Over the Past 10 Years
Min: -88.25  Med: -52.18 Max: 13.74
Current: -31.4
-88.25
13.74
ROC (Joel Greenblatt) (%) -366.05
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. AVEO: -366.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVEO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1269.33  Med: -791.02 Max: 689.47
Current: -366.05
-1269.33
689.47
Revenue Growth (3Y)(%) -8.40
AVEO's Revenue Growth (3Y)(%) is ranked lower than
66% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AVEO: -8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVEO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.55 Max: -8.4
Current: -8.4
EBITDA Growth (3Y)(%) -71.80
AVEO's EBITDA Growth (3Y)(%) is ranked lower than
99% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. AVEO: -71.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVEO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.80 Max: -2.4
Current: -71.8
EPS Growth (3Y)(%) -53.30
AVEO's EPS Growth (3Y)(%) is ranked lower than
92% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. AVEO: -53.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVEO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -54.20 Max: -2.9
Current: -53.3
» AVEO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AVEO Guru Trades in Q1 2015

Jim Simons 1,276,000 sh (+88.81%)
Paul Tudor Jones 88,219 sh (unchged)
» More
Q2 2015

AVEO Guru Trades in Q2 2015

Jim Simons 2,120,800 sh (+66.21%)
Paul Tudor Jones 82,292 sh (-6.72%)
» More
Q3 2015

AVEO Guru Trades in Q3 2015

Paul Tudor Jones 83,869 sh (+1.92%)
Jim Simons 2,091,800 sh (-1.37%)
» More
Q4 2015

AVEO Guru Trades in Q4 2015

Paul Tudor Jones 83,869 sh (unchged)
Jim Simons 1,975,900 sh (-5.54%)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.09
AVEO's P/B is ranked higher than
53% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. AVEO: 3.09 )
Ranked among companies with meaningful P/B only.
AVEO' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 2.87 Max: 22.25
Current: 3.09
0.87
22.25
P/S 2.71
AVEO's P/S is ranked higher than
81% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. AVEO: 2.71 )
Ranked among companies with meaningful P/S only.
AVEO' s P/S Range Over the Past 10 Years
Min: 0.63  Med: 4.45 Max: 101.25
Current: 2.71
0.63
101.25
Current Ratio 3.26
AVEO's Current Ratio is ranked lower than
61% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AVEO: 3.26 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.26 Max: 6.77
Current: 3.26
1.47
6.77
Quick Ratio 3.26
AVEO's Quick Ratio is ranked lower than
58% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. AVEO: 3.26 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.26 Max: 6.77
Current: 3.26
1.47
6.77
Days Sales Outstanding 89.04
AVEO's Days Sales Outstanding is ranked lower than
65% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. AVEO: 89.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 38.64 Max: 390.8
Current: 89.04
3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.68
AVEO's Price/Net Cash is ranked higher than
54% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. AVEO: 4.68 )
Ranked among companies with meaningful Price/Net Cash only.
AVEO' s Price/Net Cash Range Over the Past 10 Years
Min: 2.26  Med: 5.80 Max: 21
Current: 4.68
2.26
21
Price/Net Current Asset Value 3.07
AVEO's Price/Net Current Asset Value is ranked higher than
70% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. AVEO: 3.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVEO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.81  Med: 4.45 Max: 7.86
Current: 3.07
1.81
7.86
Price/Tangible Book 2.97
AVEO's Price/Tangible Book is ranked higher than
61% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. AVEO: 2.97 )
Ranked among companies with meaningful Price/Tangible Book only.
AVEO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.36  Med: 3.15 Max: 7.25
Current: 2.97
1.36
7.25
Price/Median PS Value 0.59
AVEO's Price/Median PS Value is ranked higher than
74% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. AVEO: 0.59 )
Ranked among companies with meaningful Price/Median PS Value only.
AVEO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.00 Max: 16.64
Current: 0.59
0.54
16.64
Earnings Yield (Greenblatt) (%) -44.82
AVEO's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. AVEO: -44.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVEO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -46.75  Med: 164.40 Max: 48140
Current: -44.82
-46.75
48140

More Statistics

Revenue(Mil) $19
EPS $ -0.28
Beta1.18
Short Percentage of Float1.24%
52-Week Range $0.82 - 3.50
Shares Outstanding(Mil)58.18

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CHMA, LSE:MTPH, TSX:QLT, NAS:PIRS, XKLS:7178, ASX:ACR » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More May 04 2016
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings? May 03 2016
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor... May 02 2016
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor... May 02 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : April 19, 2016 Apr 19 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : April 5, 2016 Apr 05 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 04 2016
Coverage initiated on AVEO Oncology by FBR Capital Mar 30 2016
Aveo Pharmaceuticals to pay $4 mln to settle kidney drug case Mar 29 2016
Feds charge Cambridge drug firm, former execs with misleading investors Mar 29 2016
SEC Charges Aveo With Misleading Investors Mar 29 2016
Aveo Pharmaceuticals to pay U.S. SEC $4 mln to settle kidney drug case Mar 29 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Mar 24 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : March 23, 2016 Mar 23 2016
AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 23 2016
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences Mar 23 2016
AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: 2015 By the Numbers Mar 22 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 21 2016
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North... Mar 21 2016
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North... Mar 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK